These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 9341912

  • 1. Phenylimidazolidin-2-one derivatives as selective 5-HT3 receptor antagonists and refinement of the pharmacophore model for 5-HT3 receptor binding.
    Heidempergher F, Pillan A, Pinciroli V, Vaghi F, Arrigoni C, Bolis G, Caccia C, Dho L, McArthur R, Varasi M.
    J Med Chem; 1997 Oct 10; 40(21):3369-80. PubMed ID: 9341912
    [Abstract] [Full Text] [Related]

  • 2. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy of arylpiperazine derivatives at the central 5-HT3 receptors.
    Cappelli A, Anzini M, Vomero S, Canullo L, Mennuni L, Makovec F, Doucet E, Hamon M, Menziani MC, De Benedetti PG, Bruni G, Romeo MR, Giorgi G, Donati A.
    J Med Chem; 1999 May 06; 42(9):1556-75. PubMed ID: 10229626
    [Abstract] [Full Text] [Related]

  • 3. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 1. Mapping the central 5-HT3 receptor binding site by arylpiperazine derivatives.
    Cappelli A, Anzini M, Vomero S, Mennuni L, Makovec F, Doucet E, Hamon M, Bruni G, Romeo MR, Menziani MC, De Benedetti PG, Langer T.
    J Med Chem; 1998 Feb 26; 41(5):728-41. PubMed ID: 9513601
    [Abstract] [Full Text] [Related]

  • 4. Synthesis and 5-HT3 receptor affinity of new quinolinecarboxylic acid derivatives.
    Orjales A, Alonso-Cires L, López-Tudanca PL, Tapia I, Labeaga L, Mosquera R.
    Drug Des Discov; 2000 Feb 26; 16(4):271-9. PubMed ID: 10807033
    [Abstract] [Full Text] [Related]

  • 5. 2,3-Dihydro-2-oxo-1H-benzimidazole-1-carboxamides with selective affinity for the 5-HT(4) receptor: synthesis and structure-affinity and structure-activity relationships of a new series of partial agonist and antagonist derivatives.
    Tapia I, Alonso-Cires L, López-Tudanca PL, Mosquera R, Labeaga L, Innerárity A, Orjales A.
    J Med Chem; 1999 Jul 29; 42(15):2870-80. PubMed ID: 10425096
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacological properties of quinoxaline derivatives as a new class of 5-HT3 receptor antagonists.
    Lasheras B, Berjón A, Montañés R, Roca J, Romero G, Ramírez MJ, Del Río J.
    Arzneimittelforschung; 1996 Apr 29; 46(4):401-6. PubMed ID: 8740088
    [Abstract] [Full Text] [Related]

  • 9. New 2-piperazinylbenzimidazole derivatives as 5-HT3 antagonists. Synthesis and pharmacological evaluation.
    Orjales A, Mosquera R, Labeaga L, Rodes R.
    J Med Chem; 1997 Feb 14; 40(4):586-93. PubMed ID: 9046349
    [Abstract] [Full Text] [Related]

  • 10. Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
    Hirokawa Y, Fujiwara I, Suzuki K, Harada H, Yoshikawa T, Yoshida N, Kato S.
    J Med Chem; 2003 Feb 27; 46(5):702-15. PubMed ID: 12593651
    [Abstract] [Full Text] [Related]

  • 11. Selective 5-hydroxytryptamine3 (5-HT3) receptor blocking activity of KB-R6933, a novel benzimidazole derivative.
    Ozaki A, Fujishima Y, Sukamoto T.
    Jpn J Pharmacol; 1999 May 27; 80(1):25-32. PubMed ID: 10446753
    [Abstract] [Full Text] [Related]

  • 12. Synthesis and structure-activity relationships of potent and orally active 5-HT4 receptor antagonists: indazole and benzimidazolone derivatives.
    Schaus JM, Thompson DC, Bloomquist WE, Susemichel AD, Calligaro DO, Cohen ML.
    J Med Chem; 1998 May 21; 41(11):1943-55. PubMed ID: 9599243
    [Abstract] [Full Text] [Related]

  • 13. New esters of 4-amino-5-chloro-2-methoxybenzoic acid as potent agonists and antagonists for 5-HT4 receptors.
    Yang D, Soulier JL, Sicsic S, Mathé-Allainmat M, Brémont B, Croci T, Cardamone R, Aureggi G, Langlois M.
    J Med Chem; 1997 Feb 14; 40(4):608-21. PubMed ID: 9046352
    [Abstract] [Full Text] [Related]

  • 14. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro.
    Wong EH, Clark R, Leung E, Loury D, Bonhaus DW, Jakeman L, Parnes H, Whiting RL, Eglen RM.
    Br J Pharmacol; 1995 Feb 14; 114(4):851-9. PubMed ID: 7773546
    [Abstract] [Full Text] [Related]

  • 15. Pinacidil suppression on 5-HT3 receptor-mediated contraction of guinea pig ileum in vitro.
    Yuan YM, Xu DY, Hu GY.
    Zhongguo Yao Li Xue Bao; 1998 Jan 14; 19(1):31-5. PubMed ID: 10375754
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Tetraethylammonium and 4-aminopyridine enhancement of 5-HT3 receptor-mediated contraction of guinea pig ileum in vitro.
    Yuan YM, Yang HH, Hu GY.
    Zhongguo Yao Li Xue Bao; 1998 Sep 14; 19(5):451-5. PubMed ID: 10375808
    [Abstract] [Full Text] [Related]

  • 18. Ligand binding to the serotonin 5HT3 receptor studied with a novel fluorescent ligand.
    Tairi AP, Hovius R, Pick H, Blasey H, Bernard A, Surprenant A, Lundström K, Vogel H.
    Biochemistry; 1998 Nov 10; 37(45):15850-64. PubMed ID: 9843391
    [Abstract] [Full Text] [Related]

  • 19. N(alpha)-imidazolylalkyl and pyridylalkyl derivatives of histaprodifen: synthesis and in vitro evaluation of highly potent histamine H(1)-receptor agonists.
    Menghin S, Pertz HH, Kramer K, Seifert R, Schunack W, Elz S.
    J Med Chem; 2003 Dec 04; 46(25):5458-70. PubMed ID: 14640554
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.